← Leaderboards
Norman K Hollenberg
Brigham And Women'S Hospital
$2,802,146
Attributed
$2,802,146
Total exposure
17
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $465.2K · FY2005–08$500K$375K$250K$125K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$2,802,146 · 17
By mechanism
P50$988,849 · 2
M01$939,692 · 14
R01$873,605 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Javid J Moslehi$8,184,260
- Rhonda Bentley-Lewis$1,412,158
- Paul R Conlin$6,611,270
- Howard D Sesso$5,697,818
- Jonathan S Williams$3,996,120
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchAngiotensin IiDiabetic NephropathyHemodynamicsKidney PharmacologyRenin Angiotensin SystemKidney FunctionGenetic SusceptibilityDrug Screening /EvaluationHyperglycemiaKidney CirculationHuman Therapy EvaluationDisease /Disorder Proneness /RiskCaptoprilGenetic PolymorphismFamily GeneticsNoninsulin Dependent Diabetes MellitusClearance RateAce InhibitorsAngiotensinogenReninInstitutionInsulin Dependent Diabetes Mellitus
Grant awards (32)
RENIN INHIBITION AND KIDNEY$36,111
M01 · FY2008 · RR · contact PI
COCOA, POLYPHENOLS AND THE KIDNEY IN HEALTHY HUMANS$10,669
M01 · FY2008 · RR · contact PI
RENIN INHIBITION AND KIDNEY$242,038
M01 · FY2007 · RR · contact PI
COCOA, POLYPHENOLS AND THE KIDNEY IN HEALTHY HUMANS$71,511
M01 · FY2007 · RR · contact PI
COCOA, POLYPHENOLS AND THE KIDNEY IN HEALTHY HUMANS$130,783
M01 · FY2006 · RR · contact PI
RENIN INHIBITION AND KIDNEY$79,678
M01 · FY2006 · RR · contact PI
INTERMEDIATE PHENOTYPE AND RISK OF DIABETIC NEPHROPATHY$257,543
P50 · FY2005 · HL
COCOA, POLYPHENOLS AND THE KIDNEY IN HEALTHY HUMANS$165,672
M01 · FY2005 · RR
THE EFFECT OF ROSIGLITAZONE ON THE INTRARENAL RENIN SYSTEM$40,636
M01 · FY2005 · RR
GENETIC PREDISPOSITION TO HYPERTENSION AND DIABETIC NEUROPATHY$1,340
M01 · FY2005 · RR
Cocoa, Polyphenols and the Kidney in Healthy Humans$101,660
M01 · FY2004 · RR
Effect of Rosiglitazone on the Intrarenal Renin System$34,617
M01 · FY2004 · RR
Renal Responses to an Antagonist, Candersartan$24,977
M01 · FY2004 · RR
RACE, RENIN, GENES, RISK, AND DIABETIC NEPHROPATHY$298,188
R01 · FY2002 · DK
INTERMEDIATE PHENOTYPE AND RISK OF DIABETIC NEPHROPATHY$237,978
P50 · FY2002 · HL
HYPERGLYCEMIA AND RENAL VASCULAR RESPONSE TO AN ANGIOTENSIN II ANTAGONIST$0
M01 · FY2002 · RR
RENAL RESPONSES TO ANGIOTENSIN II ANTAGONIST IRBESARTAN IN TYPE II DIABETES$0
M01 · FY2002 · RR
GENETIC PREDISPOSITION IN HYPERTENSION AND DIABETIC NEPHROPATHY$0
M01 · FY2002 · RR
RENAL RESPONSES TO AN ANGIOTENSIN II ANTAGONIST, CANDESARTAN$0
M01 · FY2002 · RR
RACE, RENIN, GENES, RISK, AND DIABETIC NEPHROPATHY$291,133
R01 · FY2001 · DK
INTERMEDIATE PHENOTYPE AND RISK OF DIABETIC NEPHROPATHY$0
P50 · FY2001 · HL
HYPERGLYCEMIA AND RENAL VASCULAR RESPONSE TO AN ANGIOTENSIN II ANTAGONIST$0
M01 · FY2001 · RR
RENAL RESPONSES TO ANGIOTENSIN II ANTAGONIST IRBESARTAN IN TYPE II DIABETES$0
M01 · FY2001 · RR
RENAL RESPONSES TO AN ANGIOTENSIN II ANTAGONIST, CANDESARTAN$0
M01 · FY2001 · RR
GENETIC PREDISPOSITION IN HYPERTENSION AND DIABETIC NEPHROPATHY$0
M01 · FY2001 · RR
RACE, RENIN, GENES, RISK, AND DIABETIC NEPHROPATHY$284,284
R01 · FY2000 · DK
CORE--PHYSIOLOGY AND BIOCHEMISTRY LABORATORY$246,664
P50 · FY2000 · HL
INTERMEDIATE PHENOTYPE AND RISK OF DIABETIC NEPHROPATHY$246,664
P50 · FY2000 · HL
GENETIC PREDISPOSITION IN HYPERTENSION AND DIABETIC NEPHROPATHY$0
M01 · FY2000 · RR
HYPERGLYCEMIA AND RENAL VASCULAR RESPONSE TO AN ANGIOTENSIN II ANTAGONIST$0
M01 · FY2000 · RR
RENAL RESPONSES TO AN ANGIOTENSIN II ANTAGONIST, CANDESARTAN$0
M01 · FY2000 · RR
RENAL RESPONSES TO ANGIOTENSIN II ANTAGONIST IRBESARTAN IN TYPE II DIABETES$0
M01 · FY2000 · RR